Patents Examined by Nancy A. Johnson
  • Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
    Patent number: 6024957
    Abstract: Compounds and methods are described for the differential inhibition of tyrosine phosphorylation of phospholipase C-.gamma.1 for the prevention or reversal of transplant rejection as well as therapy for autoimmune diseases. Methods for the treating or preventing tissue or organ transplant rejection and methods for treating an autoimmune disease comprising the administration of monoclonal antibodies that specifically bind to the CD45RB epitope of the CD45RB isoform are disclosed.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: February 15, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Andrew I. Lazarovits, Sibrand Poppema
  • Antibody-based method of localizing activated thrombin receptors
    Patent number: 6024936
    Abstract: The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 15, 2000
    Assignees: The Regents of the University of California, COR Therapeutics, Inc.
    Inventors: Shaun R. Coughlin, Robert M. Scarborough
  • cDNAs coding for members of the carcinoembryonic antigen family
    Patent number: 6022958
    Abstract: A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 8, 2000
    Assignee: Bayer Corporation
    Inventors: Thomas R. Barnett, James J. Elting, Michael E. Kamarck, Axel W. Kretschmer
  • Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays
    Patent number: 6013772
    Abstract: A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 11, 2000
    Assignee: Bayer Corporation
    Inventors: Thomas R. Barnett, James J. Elting, Michael E. Kamarck, Axel W. Kretschmer
  • Siva genes, novel genes involved in CD27-mediated apoptosis
    Patent number: 6010853
    Abstract: The invention provides isolated nucleic acids molecules, designated Siva nucleic acid molecules, which encode proteins involved in immune cell apoptosis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Siva nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Siva gene has been introduced or disrupted. The invention still further provides isolated Siva proteins, fusion proteins, antigenic peptides and anti-Siva antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: January 4, 2000
    Assignee: Dana-Farber Cancer Institute
    Inventors: Prasad V. S. Kanteti, Zhaohui Ao, Stuart F. Schlossman
  • Use of anhydrovinblastine
    Patent number: 6011041
    Abstract: The present invention is particularly directed to the use of a derivative of vinblastine, 3',4'-anhydrovinblastine (AHVB), which differs from vinblastine in that it possesses a double bond at the 3',4' position of the caranthine nucleus rather than the hydroxyl group that is present in the parent structure, as an antineoplastic agent in the therapeutic treatment of cancer. Specifically, the treatment of lymphoma with 3',4'-anhydrovinblastine is disclosed.
    Type: Grant
    Filed: July 26, 1996
    Date of Patent: January 4, 2000
    Assignee: University of British Columbia
    Inventors: Bruce Schmidt, James Kutney, Lawrence Mayer
  • Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof
    Patent number: 6007814
    Abstract: Therapeutic agents and methods for treating and diagnosing leukemia are provided. Such agents comprises monoclonal antibody M195, a polypeptide capable of binding to the antigen of M195, or a chimeric antibody such a peptide, conjugated to a cytotoxic agent, e.g. a radioisotope or alone. Methods for delivering genetic information to a targeted cell is also provided.
    Type: Grant
    Filed: June 15, 1992
    Date of Patent: December 28, 1999
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventor: David A. Scheinberg
  • Antibody to aminoterminal propeptide of type 1 procollagen
    Patent number: 6008325
    Abstract: Aminoterminal propeptide of type I procollagen exists in serum in two forms: classical type I procollagen which is a heterotrimer containing two pro .alpha.1-chains and one pro .alpha.2-chain of type I procollagen, and an .alpha.1-homotrimer type I procollagen containing three identical pro .alpha.1-chains. These intact, trimeric aminoterminal propeptides may be isolated without the use of proteolytic enzymes and the resultant propeptides may be used to prepare antibodies specific for the intact trimeric propeptide, having no affinity for the monomeric form of the propeptide. Such antibodies are useful in methods of assaying intact trimeric aminoterminal propeptide of type I procollagen in serum, without false information resulting from inadvertent assay of the monomeric form of the propeptide.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: December 28, 1999
    Assignee: Orion Diagnostica
    Inventors: Juha Risteli, Leila Risteli, Jukka Melkko, Saila Kauppila
  • Calcium-independent phospholipase A.sub.2
    Patent number: 6004809
    Abstract: The present invention provides a substantially pure phopholipase A.sub.2 protein isolated and purified from rabbit kidney cortex, having a molecular weight of 28 kDa as determined by SDS-PAGE, is calcium independent, is cytosolic, has a specific activity of approximately 1.2 .mu.mol/mg protein/minute and a pH optimum of approximately 7.5 and exhibits a preferential hydrolysis toward sn-2 fatty acid from diradylglycerophospholipids. Also provided are a first monoclonal antibody that specifically binds to the protein of claim 1 various methods of using, inhibiting or measuring said protein.
    Type: Grant
    Filed: June 8, 1998
    Date of Patent: December 21, 1999
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Didier Portilla, Sudhir V. Shah
  • Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
    Patent number: 6001351
    Abstract: The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-.gamma. is in a ratio such that after 60 h of activation with IFN-.gamma., the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: December 14, 1999
    Assignee: I.D.M. Immuno-Designed Molecules
    Inventors: Mohamed Chokri, Jacques Bartholeyns
  • Immunoadhesins and methods of production and use thereof
    Patent number: 5998598
    Abstract: The invention is directed toward a compound comprising a recombinant nucleic acid encoding an immunoadhesin inserted within an adenoviral nucleic acid, wherein the recombinant nucleic acid can be packaged in an adenovirus particle and wherein expression of the recombinant nucleic acid encoding the immunoadhesin results in production of the immunoadhesin protein. The recombinant nucleic acid encoding the immunoadhesin can be within an adenovirus.
    Type: Grant
    Filed: March 10, 1997
    Date of Patent: December 7, 1999
    Assignee: The United States of America, as represented by the Department of Health and Human Services
    Inventors: Karl G. Csaky, Eddy Anglade, Daniel M. Sullivan, William LaRochelle
  • Stimulation of host defense mechanisms against tumors
    Patent number: 5997858
    Abstract: A method for treating neoplastic disease in a mammal via administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact. The amount of interferon administered is less than an amount which induces a pathological response when administered parenterally.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: December 7, 1999
    Assignee: Pharma Pacific Pty Ltd.
    Inventors: Michael Gerard Tovey, Thomas James Kaido
  • Somatostatin receptor peptide antigens and antibodies
    Patent number: 5998154
    Abstract: Peptide antigens derived from the carboxy terminus of somatostatin receptors and antibodies produced using the peptide antigens. The anti-somatostatin receptor antibodies are specific for a receptor subtype and are useful in characterizing receptor subtypes expressed by tissues.
    Type: Grant
    Filed: July 7, 1995
    Date of Patent: December 7, 1999
    Assignee: The University of Texas System
    Inventor: Agnes Schonbrunn
  • Method to ameliorate osteolysis and metastasis
    Patent number: 5993817
    Abstract: Materials immunoreactive with parathyroid hormone-related protein (PTH-rp) are used in the invention method to prevent and treat cancer metastasis to bone and cancer cell growth in bone as well as osteolysis and symptomatic sequelae thereof. Antibodies with human characteristics are included in the invention for application of the invention method to human subjects.
    Type: Grant
    Filed: February 9, 1995
    Date of Patent: November 30, 1999
    Assignee: Xenotech
    Inventors: Toshiyuki Yoneda, Gregory R. Mundy, Theresa A. Guise
  • Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
    Patent number: 5994088
    Abstract: This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for purifying hematopoietic stems cells expressing Pgp and diagnostic and therapeutic methods for cancer cells expressing Pgp.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: November 30, 1999
    Assignee: Board of Trustees of the University of Illinois
    Inventors: Eugene Mechetner, Igor B. Roninson
  • Tumor associated antigen compositions and methods
    Patent number: 5993828
    Abstract: A method for inducing or enhancing in a human subject the production of antibodies reactive with the polypeptide subunit of Urinary Tumor Associated Antigen having a molecular weight of about 90 to 100 kD after reduction by .beta.-mercaptoethanol and separation by SDS-polyacrylamide gel electrophoresis is disclosed. The method comprises administering to the subject an effective dose of a composition comprising inactivated tumor cells having Urinary Tumor Associated Antigen on the cell surface and at least one tumor associated antigen selected from the group consisting of GM-2, GD-2, Fetal Antigen and Melanoma Associated Antigen.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 30, 1999
    Inventor: Donald L. Morton
  • Recombinant antibodies specific for TNF.alpha.
    Patent number: 5994510
    Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF.alpha., are provided for use in diagnosis and therapy. In particular, the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF.alpha. antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: November 30, 1999
    Assignee: Celltech Therapeutics Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage, Mark William Bodmer
  • Suppressor and progenitor cells
    Patent number: 5985656
    Abstract: Natural suppressor (NS) cells secrete a soluble protein suppressor factor (SF) which suppresses the mixed lymphocyte response. NS cells as described herein are null, i.e., have the phenotype IL-2R.sup.+, CD3.sup.-, CD4.sup.-, CD8.sup.-, TCR.alpha..beta..sup.-, Ig.sup.-, MAC-1.sup.-, or are double negative suppressors (DNS); i.e., have the phenotype IL-2R.sup.+, CD3.sup.+, CD4.sup.-, CD8.sup.-, TCR.alpha..beta..sup.+. Both NS and SF are useful in vivo to confer immunotolerance with respect to allogeneic transplants, and to effect immunosuppression. They also enhance engraftment of transplanted cells. A population of cells can be provided using density gradient separation techniques which is enriched in progenitor cells as identified by the presence of CD34 surface markers.
    Type: Grant
    Filed: November 4, 1992
    Date of Patent: November 16, 1999
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Samuel S. Strober
  • Destruction of contaminating tumor cells in stem cell transplants using bispecific antibodies
    Patent number: 5985276
    Abstract: The present invention discloses a procedure for the destruction of contaminating tumor cells in stem cell transplants ex vivo using intact bispecific antibodies.
    Type: Grant
    Filed: September 3, 1997
    Date of Patent: November 16, 1999
    Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbH
    Inventors: Horst Lindhofer, Helge Menzel, Hans-Jochem Kolb, Stefan Thierfelder
  • Antibodies to leukemia inhibitory factor
    Patent number: 5980894
    Abstract: The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.
    Type: Grant
    Filed: April 10, 1997
    Date of Patent: November 9, 1999
    Assignee: Genentech, Inc.
    Inventor: Kyung Jin Kim